Literature DB >> 27577555

Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Qingmei Jia1, Richard Bowen2, Bai-Yu Lee3, Barbara Jane Dillon4, Saša Masleša-Galić5, Marcus A Horwitz6.   

Abstract

A safer and more effective vaccine than the unlicensed Francisella tularensis Live Vaccine Strain (LVS) is needed to protect against the biowarfare agent F. tularensis. Previously, we developed an LVS ΔcapB mutant that is significantly safer than LVS and provides potent protective immunity against F. tularensis respiratory challenge when administered intranasally but limited protection when administered intradermally unless as part of a prime-boost vaccination strategy. To improve the immunogenicity and efficacy of LVS ΔcapB, we developed recombinant LVS ΔcapB (rLVS ΔcapB) strains overexpressing various F. tularensis Francisella Pathogenicity Island (FPI) proteins - IglA, IglB and IglC, and a fusion protein (IglABC) comprising immunodominant epitopes of IglA, IglB, and IglC downstream of different Francisella promoters, including the bacterioferritin (bfr) promoter. We show that rLVS ΔcapB/bfr-iglA, iglB, iglC, and iglABC express more IglA, IglB, IglC or IglABC than parental LVS ΔcapB in broth and in human macrophages, and stably express FPI proteins in macrophages and mice absent antibiotic selection. In response to IglC and heat-inactivated LVS, spleen cells from mice immunized intradermally with rLVS ΔcapB/bfr-iglC or bfr-iglABC secrete greater amounts of interferon-gamma and/or interleukin-17 than those from mice immunized with LVS ΔcapB, comparable to those from LVS-immunized mice. Mice immunized with rLVS ΔcapB/bfr-iglA, iglB, iglC or iglABC produce serum antibodies at levels similar to LVS-immunized mice. Mice immunized intradermally with rLVS ΔcapB/bfr-iglABC and challenged intranasally with virulent F. tularensis Schu S4 survive longer than sham- and LVS ΔcapB-immunized mice. Mice immunized intranasally with rLVS ΔcapB/bfr-iglABC - but not with LVS - just before or after respiratory challenge with F. tularensis Schu S4 are partially protected; protection is correlated with induction of a strong innate immune response. Thus, rLVS ΔcapB/bfr-iglABC shows improved immunogenicity and protective efficacy compared with parental LVS ΔcapB and, in contrast to LVS, has partial efficacy as immediate pre- and post-exposure prophylaxis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bioterrorism; Francisella pathogenicity island; Francisella tularensis; LVS ΔcapB; Type VI secretion system; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27577555      PMCID: PMC5028307          DOI: 10.1016/j.vaccine.2016.08.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  EVALUATION OF LIVE TULAREMIA VACCINE PREPARED IN A CHEMICALLY DEFINED MEDIUM.

Authors:  R E CHAMBERLAIN
Journal:  Appl Microbiol       Date:  1965-03

2.  Virulence of Bacterium tularense. I. A study of the virulence of Bacterium tularense in mice, guinea pigs, and rabbits.

Authors:  J F BELL; C R OWEN; C L LARSON
Journal:  J Infect Dis       Date:  1955 Sep-Oct       Impact factor: 5.226

3.  Atomic structure of T6SS reveals interlaced array essential to function.

Authors:  Daniel L Clemens; Peng Ge; Bai-Yu Lee; Marcus A Horwitz; Z Hong Zhou
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

4.  A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG.

Authors:  Marcus A Horwitz; Günter Harth; Barbara Jane Dillon; Sasa Maslesa-Galić
Journal:  Vaccine       Date:  2005-10-11       Impact factor: 3.641

5.  An outbreak of primary pneumonic tularemia on Martha's Vineyard.

Authors:  K A Feldman; R E Enscore; S L Lathrop; B T Matyas; M McGuill; M E Schriefer; D Stiles-Enos; D T Dennis; L R Petersen; E B Hayes
Journal:  N Engl J Med       Date:  2001-11-29       Impact factor: 91.245

6.  Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells.

Authors:  Amanda J Griffin; Deborah D Crane; Tara D Wehrly; Catharine M Bosio
Journal:  Clin Vaccine Immunol       Date:  2014-11-19

7.  Construction and characterization of a highly efficient Francisella shuttle plasmid.

Authors:  Tamara M Maier; Andrea Havig; Monika Casey; Francis E Nano; Dara W Frank; Thomas C Zahrt
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

8.  Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

Authors:  J Wayne Conlan; Hua Shen; Igor Golovliov; Carl Zingmark; Petra C F Oyston; Wangxue Chen; Robert V House; Anders Sjöstedt
Journal:  Vaccine       Date:  2009-12-16       Impact factor: 3.641

9.  A conserved alpha-helix essential for a type VI secretion-like system of Francisella tularensis.

Authors:  Jeanette E Bröms; Moa Lavander; Anders Sjöstedt
Journal:  J Bacteriol       Date:  2009-02-06       Impact factor: 3.490

Review 10.  The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?

Authors:  A F Kaufmann; M I Meltzer; G P Schmid
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

View more
  7 in total

1.  Listeria-Vectored Vaccine Expressing the Mycobacterium tuberculosis 30-Kilodalton Major Secretory Protein via the Constitutively Active prfA* Regulon Boosts Mycobacterium bovis BCG Efficacy against Tuberculosis.

Authors:  Qingmei Jia; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

2.  Listeria-Vectored Multiantigenic Tuberculosis Vaccine Enhances Protective Immunity against Aerosol Challenge with Virulent Mycobacterium tuberculosis in BCG-Immunized C57BL/6 and BALB/c Mice.

Authors:  Qingmei Jia; Saša Masleša-Galić; Susana Nava; Marcus A Horwitz
Journal:  mBio       Date:  2022-06-01       Impact factor: 7.786

3.  Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.

Authors:  Alison A McCormick; Aisha Shakeel; Chris Yi; Hardeep Kaur; Ahd M Mansour; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

4.  Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters.

Authors:  Qingmei Jia; Helle Bielefeldt-Ohmann; Rachel M Maison; Saša Masleša-Galić; Sarah K Cooper; Richard A Bowen; Marcus A Horwitz
Journal:  NPJ Vaccines       Date:  2021-03-30       Impact factor: 7.344

Review 5.  Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis.

Authors:  Qingmei Jia; Marcus A Horwitz
Journal:  Front Cell Infect Microbiol       Date:  2018-05-15       Impact factor: 5.293

6.  Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.

Authors:  Qingmei Jia; Richard Bowen; Barbara Jane Dillon; Saša Masleša-Galić; Brennan T Chang; Austin C Kaidi; Marcus A Horwitz
Journal:  Sci Rep       Date:  2018-05-03       Impact factor: 4.379

Review 7.  Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.

Authors:  Manfred S Green; James LeDuc; Daniel Cohen; David R Franz
Journal:  Lancet Infect Dis       Date:  2018-10-16       Impact factor: 25.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.